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Abstract Intracellular proteolytic processing of bovine leuke-
mia virus (BLV) envelope glycoprotein precursor (gp72) at the C-
terminal end of the RVRR268 J, site is an essential step for virus 
infectivity. Subtilisin/kexin-like convertases cleave proproteins at 
preferred RX(K/R)R J, sites, including those commonly found in 
viral envelope glycoprotein precursors. We first demonstrated 
that gp72 is processed into gp51/gp30 in both CV1 cells and the 
furin-deficient LoVo cells, leading us to compare the ability of 
mammalian convertases to cleave BLV gp72 in vitro. In contrast 
to the inability of the neuroendocrine PCI to cleave gp72, the 
convertases furin, PACE4, PC5-A and PC5-B, which process 
constitutively secreted precursors, can effectively cleave gp72 
into gp51/gp30. N-terminal sequence analysis of the convertase-
generated gp30 demonstrated that cleavage occurs at the in vivo-
utilized RVRRiSPV site. Such furin-, PACE4- and PC5-
mediated processing was completely inhibited by the oii-
antitrypsin variant od-PDX. Mutagenesis of the gp72 cleavage 
site into RVRG-TPV resulted in complete abrogation of gp72 
processing by endogenous CV-1 cells and by convertases in vitro. 
Since our in vitro data suggest a redundancy in the ability of the 
convertases to cleave gp72, RT-PCR analysis was used to define 
the convertases expressed in B-lymphocytes, representing one of 
the major targets of BLV infection. Our data revealed that only 
furin and the newly discovered PC7 mRNAs are expressed in 
Raji, B-Jab and LG2 cell lines. 
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1. Introduction 
Bovine leukemia virus (BLV), a retrovirus structurally and 
functionally related to the human T-lymphotropic viruses 
HTLV-I and II [1], is the etiological agent of bovine leukosis. 
It infects B-lymphocytes and induces lymphoid tumors in ru-
minants (for reviews see [2,3]). The type-I membrane-bound 
BLV envelope glycoprotein is synthesized as a 72 kDa (gp72) 
precursor that is cleaved by cellular proteases into 51 (gp51) 
and 30 (gp30) kDa mature forms. The exposed gp51 contains 
the cellular receptor-binding domain, and the membrane-
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bound gp30 is responsible for anchoring the gp51/gp30 com-
plex. The N-terminal domain of gp30 is involved in membrane 
fusion [4]. Systematic comparison of the cleavage site of differ-
ent viruses revealed the presence of a consensus cleavage se-
quence RX(R/K)R I identical to that recognized by mamma-
lian subtilisin/kexin-like proteinases [5]. Accordingly, 
intracellular proteolytic cleavage of gp72 occurs at the pro-
posed internal sequence RVRR|SPV, a process crucial for 
the infectivity of the virus [4]. So far, a total of seven mam-
malian subtilisin-like proteases have been identified: furin 
(also called PACE), PCI (PC3), PC2, PACE4, PC4, PC5-A 
(PC6-A) and its isoform PC5-B (PC6-B) and the newly dis-
covered PC7 (PC8, LPC or SPC7) (for reviews and updates 
[6-9]). While furin is ubiquitously expressed, PC7, PACE4 
and PC5 exhibit a widespread tissue distribution, and all cat-
alyze the processing of precursors within the constitutive se-
cretory pathway [6-11]. In addition, we recently showed that 
immune cells express large amounts of both furin and PC7 [9-
11]. In contrast, PCI, PC2 [9,12,13] and possibly PC5-A [14] 
are responsible for precursor processing within the regulated 
secretory pathway, mainly in endocrine and neural cells. PC4 
is specific to testicular germ cells [15]. 
Several reports implicated the mammalian subtilisin/kexin 
convertases in viral envelope precursor cleavage. Thus, in cel-
lular coexpression experiments, furin was shown to catalyze 
the proteolytic processing of Newcastle disease virus F protein 
[16], parainfluenza virus type 3 HA protein [17] and cytome-
galovirus gpUL55 protein [18], and furin, PACE4 [19,20] and 
PC7 [10] cleave HIV-1 gpl60. In vitro experiments have dem-
onstrated that furin, PACE4, PC5 as well as PCI can cleave 
the HIV-1 gpl60 into gpl20/gp41 [10,11,20,21]. Although 
these results suggest that a certain redundancy exists in the 
ability of mammalian convertases to process viral envelope 
glycoproteins, quantitation of the level of expression of the 
PCs in virus-infectable host cells should be considered. Thus, 
in the case of CD4+ T-cells, the major targets of HIV-1 in-
fection, furin and PC7 were reported to be the major PC-like 
gpl60 convertases expressed in human primary T-lympho-
cytes [10]. 
In this report, we present the first experimental evidence 
that the BLV surface glycoprotein gp72 is processed into 
gp51/gp30 in LoVo cells which are devoid of furin activity 
[22], suggesting that more than one convertase can cleave 
this precursor. This led to the in vitro demonstration that 
furin, PACE4, PC5, but not PCI, can correctly process 
gp72 into gp51/gp30. N-terminal sequence analysis of gp30 
generated by each convertase conclusively demonstrated that 
PC-preferred processing occurs at the physiological cleavage 
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site R V R R | S P V 2 7 1 [23]. Fur thermore, we could not demon-
strate a PC-mediated cleavage of mutated gp72 in which the 
processing site is replaced by RVRG-TPV. Finally, we also 
show that the PC-mediated processing of gp72 is not inhibited 
by the serpin variant ai-anti t rypsin Pittsburgh ( a l -P IT) , but 
is completely blocked by ai-ant i t rypsin Port land ( a l - P D X ) 
[24], an inhibitor whose active site sequence R-X-X-R mimics 
sites recognized by most convertases [7,9,13,20,24]. 
2. Materials and methods 
2.1. Cell culture 
CV1 [11] and LoVo [20] cells were cultivated in DMEM (Gibco Life 
technologies, Inc.) supplemented with 10% fetal calf serum (FCS), 
non-essential amino acids and kanamycin (Gibco). The cell lines 
Raji, B-Jab and LG2 were a gift of Dr. R. Sekaly (IRCM, Montreal, 
Canada). At 80% confluence, the CV1 and LoVo cells were infected 
for 1 h with a recombinant vaccinia virus carrying the env gene of 
BLV (a gift of Dr. D. Portetelle, Facultes Agronomiques de Gem-
bloux, Belgium) at a multiplicity of infection of one plaque forming 
unit/cell. Following infection, the cells were grown for 6 h and then 
lysed in RIPA buffer [20] and the lysate run on 10% SDS-PAGE, 
blotted onto a nitrocellulose membrane which was then analyzed by 
Western blotting using a cocktail of monoclonal anti-gp72 antibodies 
(a gift of Dr. D. Portetelle). Immunoreactive proteins were reacted 
with a secondary antibody coupled to alkaline phosphatase, followed 
by coloration with the substrate nitroblue tetrazolium 5-bromo-4-
chloro-3-indolylphosphate (NBT-BCIP; Boehringer Mannheim). 
2.2. Purification of gp72 
The procedure used to purify BLV gp72 was described by Decroly 
et al. [21]. Briefly, CV1 cells were infected with recombinant vaccinia 
virus carrying the env gene of BLV at a multiplicity of infection of one 
plaque forming unit/cell. Twenty hours post infection, CV1 cells were 
starved of cysteine or leucine for 1 h in a DMEM cysteine- or leucine-
free medium containing 5% FCS. The cells were then labeled in the 
same medium supplemented with [35S]Cys or [3H]Leu (ICN Flow). 
After 1 h labeling, the cells were lysed in 30 mM Tris, 150 mM 
NaCl, 1%> Triton X-100 pH 7.4. The clarified lysate was then purified 
on a lentil lectin agarose column (Pharmacia). After several washes 
with lysis buffer, gp72 was eluted in the same buffer containing 0.5M 
a-methylmannopyranoside (Sigma). 
2.3. Enzyme production and fluorimetric assays 
Shed-furin, BCRD-furin, PACE4, PCI, PC5-A and shed-PC5-B 
were isolated from the medium of GH4C1 cells infected with vaccinia 
virus recombinants expressing each protease gene as described 
[11,21,25,26]. Enzyme activity was tested on 200 uM of the fluoro-
genic peptide pGluArgThrLysArg-AMC (Peptide Institute, Inc., Ja-
pan) [26]. The reactions were carried out in 50 mM Tris-acetate buffer, 
1% TX-100, 4 mM CaCl2 pH 6 for PCI and 1 mM CaCl2 pH 7 for 
the other enzymes. After overnight incubation at 25°C, the reactions 
were stopped by the addition of 25 (il of glacial acetic acid. Fluores-
cence of free 7-amino-4-methylcoumarin (AMC) was measured with a 
spectrofluorimeter using 370 nm as excitation wavelength and 460 nm 
as emission wavelength. 
2.4. Endoproteolytic cleavage of gp72 
Enzymes (50 nmol AMC cleaved/h) were added to gp72 in 50 mM 
Tris-acetate, 1% Triton X-100, 4 mM CaCl2 pH 6 for PCI and 1 mM 
CaCl2 pH 7 for shed-furin, BCRD-furin, PACE4, PC5-A or shed-
PC5-B. After overnight digestion at 25°C, samples were run on a 
10% SDS-polyacrylamide gel. The gel was then dried and autoradio-
graphed on Kodak X-omat AR films. A 200-fold concentrated super-
natant of GH4C1 cells infected with recombinant vaccinia virus ex-
pressing either al-PDX or al-PIT [11] was used as a source of 
inhibitors. Inhibition experiments of the in vitro PC-mediated proc-
essing of radiolabeled gp72 using either al-PDX or al-PIT were done 
as described [11]. 
2.5. Microsequencing of the f3Hj'Leu-labeled gp30 
For microsequencing purposes, [3H]leucine-labeled gp72 was incu-
bated with the soluble shed-furin, BCRD-furin, PACE4, PC5-A or 
shed-PC5-B and the products separated on a 10%. polyacrylamide 
SDS-PAGE. The gel was then blotted on a PVDF membrane, auto-
radiographed and the dissected gp30 containing band was layered 
over a protein filter (Beckman Instruments, Inc.). Microsequencing 
was performed on a Beckman LF3400 protein sequencer (Beckman 
Instruments, Inc.). All samples were sequenced using a standard Beck-
man sequencer procedure 4. The radioactivity recovered in each cycle 
was estimated by scintillation counting using liquid scintillation ana-
lyzer Tri-Carb model 1600CA. 
2.6. Convertases detection by semi-quantitative RT-PCR 
The RNAs were isolated from 107 B-lymphocytic cells (Raji, B-Jab 
and LG2) using the TRIAzol (Gibco) procedure. RT-PCR and cDNA 
quantitation were performed as described by Decroly et al. [11]. 
3. Results and discussion 
3.1. Cellular processing of BL V gp72 
The ubiquitously expressed convertase furin has been re-
ported to be a major intracellular processing enzyme of 
most precursors transiting through the constitutive secretory 
pathway and exhibiting the consensus RX(K7R)R sequence 
[6,7,9]. Since such a motif is found at the putative processing 
site of gp72 [4], we first tested the cellular processing of this 
precursor in LoVo cells which are devoid of furin activity [22]. 
Fig. 1 shows the results of Western blot analysis of cell lysates 
obtained 6 h following vaccinia virus infection with VV:gp72 
























Fig. 1. gp72 Western blot of CV-1 and LoVo cell lysates. The cells 
were lysed 6 h post-infection by W:gp72, and run on 10% SDS-
PAGE. The cocktail of monoclonal antibodies used recognizes gp72 
and gp52 but not gp30. 











































gesting that endogenous enzymes in both cells can process 
gp72. No gp30 is detected in this system as it is not recognized 
by our monoclonal antibody cocktail (D. Portetelle, personal 
communication). Since LoVo cells are defective in furin activ-
ity, these results clearly demonstrate that in these cells, en-
zymes distinct from furin can process gp72 into gp51/gp30. 
However, furin may also participate in this processing since 
co-expression of W : furin and W:gp72 in CV-1 cells in-
creased the level of gp51 production (not shown). Because 
mammalian PCs are likely candidates for such processing, it 
is thus possible that apart from furin, either PACE4, PC5 or 




S-Cys] BLV gp72 
Fig. 2. In vitro processing of gp72 by convertases. Autoradiography 
of the 10% SDS-PAGE sepration of the in vitro cleavage products 
of the [35S]cysteine-labeled gp72 (5000 cpm) digested overnight with 
50 nmol AMC/h equivalent convertase activities, based on the diges-
tion of pERTKR-MCA. The soluble tested enzymes are shown. The 
negative control represents digestion with the equivalent volume of 
concentrated medium obtained from GH4C1 cells infected with 
wild-type vaccinia virus. The position of undigested gp72 is also 
shown. 
ney CV1 cells. The data reveal that processing of gp72 into 
gp51 occurs to about the same extent in both cell lines, sug-
3.2. In vitro cleavage of gp72 by mammalian convertases 
In an effort to identify the candidate convertases implicated 
in the cleavage of the BLV precursor, gp72 was incubated in 
vitro with several mammalian subtilisin-like endoproteases. 
These included the shed form of furin which is secreted into 
the medium [27], its isoform lacking the Cys-rich domain 
called BCRD-furin [11], PACE4 [20], PCI [26], PC5-A and 
its isoform shed PC5-B [11,14]. Since membrane-bound PC7 
([8]; Munzer and Seidah, unpublished data) is not secreted 
into the medium [11], we have not studied this enzyme in 
vitro. 
The glycoprotein gp72 was produced in CV1 cells following 
1 h infection with W:gp72 and 20 h growth. After 1 h of 
metabolic labeling with [35S]cysteine and purification on a 
lentil lectin column, the affinity purified gp72 was used for 
in vitro assays. As a source of enzymes, we used a 20-fold 
concentrated medium of GH4C1 cells infected with vaccinia 
virus recombinants that express each protease [11,21]. The 

















- ■ Shed-PC5B 
I 
8 10 12 16 
1 2 3 4 5 6 7 8 9 10 1 1 1 2 13 14 15 16 17 
Ser Pro Val Ala Ala Leu Thr Leu Gly Leu Ala Leu Ser Val Gly Leu Thr 
Cycle Number 
Fig. 3. Microsequence identification of gp72 processing site recognized by convertases. N-terminal microsequencing of [3H]Leu-labeled gp30 de-
rived from the processing of gp72 by either shed-furin, BCRD-furin, PACE4, PC5-A or shed-PC5-B. The deduced Leu positions are empha-
sized, together with the primary sequence surrounding the gp51/gp30 cleavage site [23]. 
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,35 S-Cys] BLV gp72 
Fig. 4. Site-directed mutagenesis of the gp72 processing site. This 
figure shows the effect of substitution of the gp72 cleavage site 
RVRR268J.SP [23] by RVRG-TP [4] on its proteolytic cleavage by 
convertases-The data show that all tested PCs do not process the 
mutant, as compared with shed-furin which processes the wild-type 
sequence. The experimental conditions are the same as in Fig. 2. 
level of active enzyme was evaluated on a pentapeptide fluo-
rogenic substrate pERTKR-MCA [11,21,26], whereby we used 
in all incubations with gp72 (Fig. 2) an enzymatic activity 
equivalent to 50 nmol AMC cleaved/h. 
The data in Fig. 2 demonstrate that except for PCI, the 
convertases BCRD-furin, shed-furin, shed-PC5-B, PACE4 
and PC5-A cleave gp72 in vitro, generating gp51 and gp30. 
The concentrated medium of GH4C1 cells infected with the 
wild-type vaccinia virus, used as negative control, did not 
reveal appreciable pentapeptide or gp72 converting activity 
(Fig. 2). To locate the BLV cleavage site recognized by each 
convertase, gp72 protein was labeled with [3H]leucine and 
incubated with shed-furin, BCRD-furin, PACE4, PC5-A and 
shed-PC5-B. The digestion products of [3H]leucine-labeled 
gp72 were separated on SDS-PAGE and transferred onto a 
PVDF membrane. The band corresponding to gp30 was ex-
cised and the protein microsequenced. The relative distribu-
tion of leucines along the sequence (at positions 6,8,10,12 and 
16) (Fig. 3) demonstrate unambiguously that cleavage occurs 
at the Arg268 in the sequence ArgValArgArg2681 SerProValA-
laAlaLeuThrLeuGlyLeuAlaLeuSerValGlyLeuThrGly, as ob-
served in the mature virus [23]. Thus, the in vitro data suggest 
that more than one PC can process gp72. The physiological 
enzyme(s) responsible for the processing of gp72 in vivo will 
depend on other parameters such as their co-localization in 
the same cells infected by BLV, and within the same intra-
cellular secretory pathway. 
Interestingly, PCI, which cleaved HIV gpl60 in vitro [21], 
has no activity on gp72 at 50 nmol AMC/h (Fig. 2) and only 
weak activity on BLV gp72 at 250 nmol AMC/h (not shown). 
Gotoh et al. [16] also observed a lack of in vitro cleavage of 
the NDV F0 precursor when PCI was used. This result may 
be rationalized by the presence of a proline residue at position 
P2' from the processing site RVRR|SPV of gp72. Indeed, it 
was previously observed that unlike PC2, the convertase PCI 
does not process ACTH 1-39 into ACTH 1-17 involving 
cleavage at the VGKKR J, RPV where proline occupies the 
P2' position [28]. 
Voneche et al. demonstrated that replacement of the gp72 
cleavage site by RVRG268-TP prevented the processing of this 
envelope glycoprotein by cellular convertases and abolished 
BLV-induced syncytia formation [4]. In accordance with these 
cellular data, the results of Fig. 4 demonstrate that no con-
vertase can process this gp72 mutant, suggesting that a PC-
like enzyme(s) could be implicated in the processing of gp72 in 
vivo. These data emphasize the critical importance of Arg268 
in gp72 processing. Similarly, a point mutation (Arg511 to Ser) 
at the HIV-1 gpl60 cleavage site (REKR5 1 1 i) completely 
prevented its processing [29]. It is unlikely that the lack of 
cleavage of the mutated gp72 is due to the substitution of 
serine (S; at PI ') by threonine (T). Indeed, systematic site-
directed mutagenesis of hemagglutinin obtained from a viru-
lent avian influenza virus revealed that the substitution of the 
cleavage site R K K R | G L by R K K R | T L does not signifi-
cantly affect the maturation of the HA precursor by furin 
or PC5 [30]. 
3.3. Inhibition of gp72 processing by al-PDX 
In order to identify inhibitors of the gp72 cleavage we 
tested in vitro either the al-PIT or the al-PDX [24] obtained 
from the 20-fold concentrated medium of GH4C1 cells in-
fected with their respective recombinant vaccinia viruses. 
Our data show that like the HIV-1 gpl60 processing 
[10,20,24], od-PIT does not affect the processing of gp72 by 
any of the enzymes tested (not shown). In contrast, the serpin 
variant al-PDX completely inhibits the in vitro shed-furin, 
BCRD-furin, PACE4, PC5-A and shed-PC5-B cleavage of 
gp72 (Fig. 5). This finding confirms that al-PDX is not a 
specific inhibitor of a single convertase at the exclusion of 




























[ SCys] BLV gp72 
Fig. 5. Inhibition of gp72 processing by al-PDX. Autoradiogram of 
a 10% SDS-PAGE separation of the processing products of [35S]Cys 
gp72 by shed-furin (control) and by all other convertases tested in 
the presence of al-PDX, as described [11]. 
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Fig. 6. Identification of precursor convertases mRNA in human B-
lymphocyte-derived Raji cells. Each RT-PCR amplification (28 
cycles) was performed using convertase specific primers together 
with two others specific for the control ribosomal L27 protein, as 
described [11]. RT-PCR products were separated on agarose gel 
(1.8%) electrophoresis and the relative amounts of each convertase 
in the tested lymphocyte cells were quantitated by densitometric 
analysis. The bar graphs represent the quantitation of the relative 
amount of each convertase normalized to the control L27. The data 
are an average (± standard deviation) RT-PCR experiment per-
formed on RNA isolated from quintuple values obtained from five 
different RT-PCR amplifications. 
the others. Indeed, in other systems, cd-PDX has been shown 
to inhibit furin [24] but also PACE4 and PC5 both ex vivo 
[20] and in vitro [10]. These observations provide proof of 
function of the PCs in the processing of viral glycoproteins 
and suggest that wide-specificity inhibitors could have poten-
tial applications in antiviral therapy. 
3.4. Expression of the convertases in B-lymphocyte-derived cell 
lines 
Our in vitro data suggested a certain redundancy in the 
ability of the convertases to process the BLV gp72. Since B-
lymphocytes represent one of the major targets of BLV infec-
tion, we used a semi-quantitative RT-PCR assay to detect the 
mRNA corresponding to each convertase [11] in the B-lym-
phocyte-derived Raji cell line. Under resting conditions, in 
these cells, furin and PC7 were the only significantly tran-
scribed convertases (Fig. 6). In contrast, we did not detect 
significant mRNA levels of PCI, PC2, PACE4 or PC5 in 
this cell line, as opposed to a positive control which consists 
of a mixture of human pituitary and HT-29 cells [11] which 
expresses all of them (not shown). In order to assess the gen-
erality of this relative mRNA distribution, we confirmed that 
furin and PC7 are also the only PCs expressed in two other B-
lymphocyte-derived cell lines B-Jab and LG2 (data not 
shown). These data suggest that the convertases mediating 
the gp72 cleavage in infected B-lymphocytes may be restricted 
to furin and the newly discovered enzyme PC7, both of which 
are highly enriched in lymphoid-associated tissues [8-10]. 
The absence or the low expression levels of PACE4 and 
PC5 in the tested B-lymphocyte-derived cell lines suggests 
that these convertases cleaving in vitro the BLV gp72 protein 
may not play a significant role in BLV-infected B-cells. Never-
theless, in view of the plasticity of cellular expression of the 
convertases in lymphocytes before and after immune cell acti-
vation [10,21], the determination of the convertases expressed 
in BLV-infected B-cells could be helpful to identify the en-
zymes implicated in gp72 processing in vivo. In conclusion, 
our data demonstrate that at least furin is one of the gp72 
convertases and that the newly discovered PC7 is also a plau-
sible physiological candidate in B-lymphocytes. 
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